Registry Study for COVID19 Vaccination Efficacy in Patients With a Treatment History of Rituximab.
Registry Study for COVID19 Vaccination Efficacy in Patients With a Treatment History of Rituximab.
Patients with treatment history of rituximab since 01.01.2019 and immunocompetent volunteers will be contacted to give a blood sample after their COVID19 vaccination, and in a subset also before vaccination. Immune responses of antibodies and SARS-CoV2-specific T-cells to the vaccination will be quantified and the rituximab effect on COVID19 vaccine-induced immune responses is analyzed.
Inclusion Criteria:
Exclusion Criteria:
Exclusion criteria for patients (any of the following)
Exclusion criteria for volunteers (any of the following)
daniel.sidler@insel.ch0041316323144
matthias.moor@insel.ch0041316323144